Pain management physicians occupy a specific place in the regenerative-medicine conversation, because pain management is one of the three therapy areas named in Florida’s stem cell law. That has prompted interest in whether banking a patient’s own tissue fits a pain practice. This guide separates the two activities, reads the law accurately, and lays out the logistics, patient framing, and documentation that responsible integration requires.
TLDR: Florida SB 1768 names pain management as one of three areas where physicians may administer non-FDA-approved stem cell therapy, but administering therapy and banking a patient’s own tissue for preservation are different activities, and the statute governs the former. The law also requires accredited-facility sourcing, and credible analyses read its permitted sources as excluding adipose-derived cells, which any pain practice must confirm with counsel. The adipose research relevant to pain and nerve conditions is early, and no adipose-derived product holds FDA approval for chronic pain. Banking preserves a patient’s own tissue under 21 CFR Part 1271; it is not a pain treatment and guarantees no eligibility, access, or clinical benefit.
Important Disclaimer: Save My Fat does not provide FDA-approved treatments or cures for any disease, including chronic pain conditions. No adipose-derived stem cell product currently has FDA approval for chronic pain. Banking adipose tissue today does not guarantee eligibility, access, or clinical benefit from any future therapy, clinical trial, or medical program. All content is for educational purposes only and does not constitute medical advice. Patients must consult their own licensed healthcare professionals regarding all medical decisions.
Pain patients often arrive having exhausted other options, which makes accurate communication especially important. The sections below explain where pain management sits in the law, what the evidence honestly shows, and how a preservation service can be handled without implying relief that is not established.
Where Pain Management Sits in the FL SB 1768 Framework
Florida Statutes Section 458.3245, effective July 1, 2025, permits a physician to administer non-FDA-approved stem cell therapy when the use is within the physician’s scope and relates to one of three areas: orthopedics, wound care, or pain management. Pain management is therefore named in the statute, which is the source of much of the interest among pain physicians.
Two qualifications are essential. First, the law governs administering therapy, not banking. Banking is the preservation of a patient’s own tissue for potential future use, and it is a separate activity that the statute does not convert into a therapy pathway. Second, the law requires that any cells used in therapy come from an FDA-registered facility accredited by a recognized body, with a post-thaw viability report, and credible legal and industry analyses read the statute as excluding adipose-derived mesenchymal stem cells as a permitted therapy source. That reading is consequential for any pain practice considering adipose-related therapy and must be confirmed with qualified counsel.
For a practice-level walk-through of the statute’s obligations, the SB 1768 checklist provides detail. The key point for this audience is that being named in the law does not mean adipose-derived therapy is permitted under it, and it does not mean banking is authorized by it.
What the ADSC Pain and Nerve Research Pipeline Shows
The research connecting adipose-derived cells to pain and nerve conditions is early and exploratory. Interest stems from the studied influence of mesenchymal cells on inflammatory and cellular signaling, which is why these cells appear in research touching neuropathic and inflammatory pain. This is a set of investigational questions, not an approved therapy.
Registered trials illustrate how preliminary the field is. A small Phase 1 study of autologous adipose-derived cells for intervertebral disc degeneration and low back pain, NCT02338271, enrolled roughly ten participants, and a separate early Phase 1/2 study of an autologous adipose-derived cell preparation in chronic low back pain from lumbar disc degeneration, NCT05011474, enrolled only a handful. Both are small, early, and carry status entries that have not been recently updated on ClinicalTrials.gov, which underscores how thin the controlled evidence remains. For the underlying science, the overview of nerves and pain describes how adipose-derived cells are being studied in this space.
An honest characterization avoids overstatement. The evidence base specific to adipose-derived cells in chronic pain is limited, controlled data are sparse, and no adipose-derived product holds FDA approval for any pain indication. The FDA has published consumer information cautioning patients about unapproved regenerative medicine products marketed for a range of conditions, a caution a pain physician should reinforce. The field should be treated as preliminary and communicated that way.
Harvest in a Pain Management Practice: Logistics
Many pain practices do not routinely perform fat harvesting, so a banking collection is typically coordinated through an appropriate procedural workflow rather than added casually to a clinic visit. The harvest for banking is a collection step whose purpose is preservation, and it should be handled under proper conditions with documentation.
The provider-facing overview of the harvest procedure outlines how collection, handling, and transfer are structured. Practically, this means arranging the collection in a suitable setting, maintaining sterile technique, and transferring the tissue to the processing and storage partner under documented chain-of-custody. None of this involves administering a therapy, and a pain practice should keep that boundary explicit.
Patient Conversation Framing for Pain Patients
The patient conversation in a pain practice carries particular weight, because patients in persistent pain are understandably motivated to hear hope. The honest framing is that banking is a preservation decision made under uncertainty, that it is not a pain treatment, and that it does not guarantee access to any future therapy or trial. Setting that expectation protects the patient and the practice.
It also helps to direct patients to verifiable information and to be candid about the evidence. A physician can explain that adipose-derived research in pain is early, that no adipose-derived product is FDA-approved for chronic pain, and that banking does not create eligibility for any study. The explanation of why physicians add banking describes the service model honestly for patients who ask what it is.
Documentation and Consent Checklist
Banking requires separate, specific informed consent, distinct from consent for any pain procedure the patient undergoes. The consent should state that banking is preservation, not treatment, and that it guarantees no future access or benefit. The requirements for this consent are summarized in the overview of informed consent for tissue banking.
The service operates under 21 CFR Part 1271, the federal framework governing screening, handling, and storage of human cells and tissues. Documentation should record that the patient was counseled that banking is not a treatment, retain the banking partner’s regulatory status, and keep banking records separate from clinical care records. A short documentation list helps: confirm separate banking consent, record the educational nature of the discussion, retain partner regulatory documentation, and maintain chain-of-custody records.
Physician Action Checklist
A condensed action list for a pain management practice:
- Confirm with counsel how SB 1768 applies, including that banking is distinct from administering therapy and that the adipose permitted-source question is resolved.
- Implement separate, specific banking consent that disclaims treatment and any guarantee of benefit.
- Arrange a documented harvest and chain-of-custody workflow through an appropriate procedural setup.
- Verify and retain the banking partner’s 21 CFR Part 1271 regulatory status.
- Audit patient-facing language so it never implies banking relieves or treats pain.
Frequently Asked Questions
Pain management is named in SB 1768, so does that authorize adipose banking?
No. The statute names pain management as an area where physicians may administer non-FDA-approved therapy, but it governs administering therapy, not banking, which is a separate preservation activity. Credible analyses also read the law as excluding adipose-derived cells as a permitted therapy source, which counsel should confirm.
Is there an FDA-approved adipose stem cell therapy for chronic pain?
No. Adipose-derived cells are being studied in pain and nerve research, but the work is early and no adipose-derived product holds FDA approval for any pain indication.
Does banking treat or relieve pain?
No. Banking is collection and preservation of a patient’s own tissue for potential future use. It is not a pain treatment and should not be presented as one.
Does a pain practice need to administer therapy to offer banking?
No. Banking involves collection and preservation only. The harvest is coordinated through an appropriate procedural workflow, and the tissue is transferred to a processing and storage partner. No therapy administration is involved.
How is adipose tissue banking regulated?
Banked adipose tissue is handled under 21 CFR Part 1271, the federal framework governing screening, processing, and storage of human cells and tissues.
Key Takeaways
For pain management physicians, the law’s mention of pain management is real but narrow, and it should not be read as more than it is. Florida SB 1768 names pain management as one of three areas where physicians may administer non-FDA-approved stem cell therapy, but administering therapy and banking a patient’s own tissue are different activities, and the statute governs the former while requiring accredited sourcing and, on credible readings, excluding adipose-derived cells as a permitted source. The adipose research relevant to pain and nerve conditions is early, and no adipose-derived product holds FDA approval for chronic pain. A harvest can be coordinated through a proper procedural workflow, but only with separate banking consent, documented chain-of-custody, and a verified partner operating under 21 CFR Part 1271. Above all, banking adipose tissue is a preservation service for potential future use; it is not a pain treatment, and it does not guarantee eligibility, access, or clinical benefit.
Save My Fat operates as a tissue preservation service, not a medical practice or treatment provider. Stem cell and regenerative medicine regulations vary by state, including specific informed-consent and disclosure requirements in Florida, Utah, and Nevada governing tissue and stem cell services. Banking adipose tissue does not connect patients to any treatment pathway, and any future use depends on FDA regulatory status, physician guidance, and the availability of approved or investigational pathways at that time.
Pain management practices evaluating whether to add a preservation service can review the service model and contact the team to discuss integration and documentation requirements.
Save My Fat partners with L2 Bio for laboratory processing and storage.
This article is for educational purposes only and does not constitute medical or legal advice. Legal and medical review including pain management input is required before publication. Please consult your pain management physician before making any decisions about treatment or research participation.
Related guide: the physician resource center.
